Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. 

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Novo #Nordisk #shares #pop #earlystage #weight #loss #drug #trial #results

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up